Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs... Show more
On May 08, 2025, the Stochastic Oscillator for PTGX moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 52 instances where the indicator left the oversold zone. In of the 52 cases the stock moved higher in the following days. This puts the odds of a move higher at over .
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where PTGX's RSI Oscillator exited the oversold zone, of 17 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PTGX advanced for three days, in of 305 cases, the price rose further within the following month. The odds of a continued upward trend are .
PTGX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on May 13, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on PTGX as a result. In of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for PTGX turned negative on May 05, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .
PTGX moved below its 50-day moving average on May 01, 2025 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for PTGX crossed bearishly below the 50-day moving average on April 30, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PTGX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for PTGX entered a downward trend on April 21, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PTGX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock slightly better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.937) is normal, around the industry mean (14.386). P/E Ratio (56.115) is within average values for comparable stocks, (64.760). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.146). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (13.680) is also within normal values, averaging (254.479).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
a developer of disulfide-rich peptides
Industry Biotechnology
A.I.dvisor indicates that over the last year, PTGX has been loosely correlated with MLYS. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if PTGX jumps, then MLYS could also see price increases.
Ticker / NAME | Correlation To PTGX | 1D Price Change % | ||
---|---|---|---|---|
PTGX | 100% | -2.21% | ||
MLYS - PTGX | 48% Loosely correlated | +1.20% | ||
CKPT - PTGX | 47% Loosely correlated | -0.24% | ||
TRVI - PTGX | 42% Loosely correlated | -3.66% | ||
VRDN - PTGX | 38% Loosely correlated | -2.36% | ||
FULC - PTGX | 38% Loosely correlated | +1.94% | ||
More |